Background: Bortezomib is an inhibitor of proteasome and NF-κB, with activity in various
solid tumors and hematological malignancies. Aim: The aim of the study was the analysis of …

Introduction: To study the effect of bortezomib alone or in combination with daunorubicin
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …

Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …

The proteasome inhibitor, bortezomib, is known to be effective in the therapy of various
neoplasms. The objective of this study was the analysis of the ex vivo activity of bortezomib …

We explored the safety and efficacy of bortezomib given as single agent in patients with
untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional …

[Background]: Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …

The aim of this study is to clarify the efficacy of proteasome inhibitor bortezomib to multidrug
resistant (MDR) acute leukemia cells. We observed the effects of bortezomib on a P …

Bortezomib represents a new class of anti-cancer drugs, the proteasome inhibitors. We
evaluated the in vitro activity of bortezomib with regard to tumour-type specificity and …

Abstract Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented
antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a …

Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We
conducted this phase I study to determine if the proteasome inhibitor bortezomib could be …